FDA accepts Supplemental NDA for KRAZATI® (adagrasib) – Cetuximab combo for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or mCRC February 26, 2024
Positive EU CHMP Opinion for KEYTRUDA in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence February 26, 2024
Orphan Drug Designation Granted by US FDA for IO-202 (Anti-LILRB4) for the Treatment of Chronic Myelomonocytic Leukemia (CMML) February 26, 2024
